Mengis Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Mengis Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-25,545	Closed	-$17K	–	179
2020 Q4	$17K	Hold	25,545	–	–	﹤0.01%	162
2020 Q3	$57K	Hold	25,545	–	–	0.02%	156
2020 Q2	$91K	Hold	25,545	–	–	0.03%	151
2020 Q1	$97K	Hold	25,545	–	–	0.03%	154
2019 Q4	$76K	Buy	+25,545	New	+$66.4K	0.02%	162

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Mengis Capital Management's BMY.RT Position: Q1 2021 in Review

Mengis Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 25,545 shares — an estimated $17K sold.

Mengis Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $97K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Mengis Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Mengis Capital Management sold 25,545 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $17K.
Mengis Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Mengis Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $97K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Mengis Capital Management's 13F filing for Q1 2021, filed 7 May 2021.